Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antaiwei granules
- Development stage
- Phase 3
- Lead developer
- Tasly Pharmaceutical
- Administration
- Oral
01
Overview
Antaiwei granules (安泰微颗粒) is a Traditional Chinese Medicine (TCM) therapeutic developed by Tasly Pharmaceutical Group. It is classified as a Class 1.1 new TCM drug in China, indicating a novel formulation or clinical application. The drug is specifically indicated for the treatment of the common cold with a 'wind-cold' pattern, a TCM diagnostic category characterized by symptoms such as chills, fever, headache, and lack of sweating. It is currently undergoing Phase III clinical evaluation (e.g., trial CTR20233850) to assess its efficacy and safety in adult patients. The formulation is delivered as oral granules and aims to provide symptomatic relief through the combined pharmacological activities of its constituent herbal ingredients, which typically involve antipyretic and anti-inflammatory effects.
- Brand names
- Antaiwei
- Other names
- 安泰微颗粒Antaiwei keli
Beyond the preview
Go deeper on Antaiwei granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antaiwei granules.